SuzanneShustermanMD

Clinical Trials

• Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Start of enrollment: 2004 Mar 15

  Completed

  Phase 3

• Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04

  Completed

  Phase 3

• Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25

  Recruiting

• hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma Start of enrollment: 2005 Aug 01

  Completed

  Phase 2

• Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Start of enrollment: 2004 Apr 01

  Active, not recruiting

  Phase 3

• Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Start of enrollment: 2005 Nov 14

  Completed

  Phase 3

• N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Start of enrollment: 2005 Dec 01

  Completed

  Phase 1

• Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Start of enrollment: 2007 May 03

  Completed

  Phase 3

• Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate Start of enrollment: 2006 Mar 01

  Completed

  Phase 1

• Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Start of enrollment: 2006 Jun 01

  Completed

  Phase 2

• Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Start of enrollment: 2007 Aug 06

  Active, not recruiting

  Phase 3

• A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias Start of enrollment: 2006 May 01
• Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Start of enrollment: 2006 Nov 06

  Active, not recruiting

  Phase 3

• Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Start of enrollment: 2006 Dec 26

  Completed

  Phase 3

• Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2007 Mar 01

  Completed

  Phase 3

• Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Start of enrollment: 2007 Mar 01

  Completed

  Phase 3

• Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Start of enrollment: 2008 Apr 01

  Completed

  Phase 2

• Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2009 Jan 01

  Completed

  Phase 2

• Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment Start of enrollment: 2009 Apr 01

  Completed

  Phase 1

• N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2009 Dec 01

  Completed

  Phase 1

• Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Start of enrollment: 2009 Jun 01

  Completed

  Phase 1

• Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Start of enrollment: 2009 Jun 01

  Terminated

  Phase 1

• Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13

  Active, not recruiting

  Phase 3

• N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Start of enrollment: 2010 Mar 01

  Completed

  Phase 1

• Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2009 Dec 21

  Completed

  Phase 3

• Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2010 Jun 01

  Completed

  Phase 1

• Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Start of enrollment: 2011 Feb 09

  Completed

  Phase 1, Phase 2

• Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2011 Sep 01

  Completed

  Phase 2

• Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma Start of enrollment: 2011 Dec 01

  Completed

  Phase 2

• Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma Start of enrollment: 2012 Aug 01

  Completed

  Phase 2

• Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04

  Active, not recruiting

  Phase 1

• Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Start of enrollment: 2013 Aug 28

  Completed

  Phase 1

• N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16

  Active, not recruiting

  Phase 1

• 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01

  Completed

  Phase 2

• Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08

  Active, not recruiting

  Phase 2

• Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06

  Active, not recruiting

  Phase 1, Phase 2

  Roles: Contact, Principal Investigator

• NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Start of enrollment: 2017 Sep 05

  Active, not recruiting

  Phase 1

  Roles: Contact

• Neuroblastoma Biology Study Start of enrollment: 2011 Jul 01

  Recruiting

  Roles: Contact

• MIBG With Dinutuximab +/- Vorinostat Start of enrollment: 2018 Sep 12

  Active, not recruiting

  Phase 1

  Roles: Contact

• NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial Start of enrollment: 2024 Jul 01

  Not yet recruiting

  Phase 2

  Roles: Contact

• Join now to see all